US20020010148A1 - Oral combinations of hydroxocobalamin and folic acid - Google Patents
Oral combinations of hydroxocobalamin and folic acid Download PDFInfo
- Publication number
- US20020010148A1 US20020010148A1 US09/534,417 US53441700A US2002010148A1 US 20020010148 A1 US20020010148 A1 US 20020010148A1 US 53441700 A US53441700 A US 53441700A US 2002010148 A1 US2002010148 A1 US 2002010148A1
- Authority
- US
- United States
- Prior art keywords
- vitamin
- formulation according
- hydroxocobalamin
- folic acid
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 title claims abstract description 84
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title claims abstract description 68
- 235000004867 hydroxocobalamin Nutrition 0.000 title claims abstract description 42
- 239000011704 hydroxocobalamin Substances 0.000 title claims abstract description 42
- 229960001103 hydroxocobalamin Drugs 0.000 title claims abstract description 42
- 235000019152 folic acid Nutrition 0.000 title claims abstract description 38
- 239000011724 folic acid Substances 0.000 title claims abstract description 38
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 229960000304 folic acid Drugs 0.000 title claims abstract description 31
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 57
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 57
- 238000009472 formulation Methods 0.000 claims abstract description 32
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims description 25
- 230000007812 deficiency Effects 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 20
- 239000011726 vitamin B6 Substances 0.000 claims description 14
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 8
- 235000020774 essential nutrients Nutrition 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 claims description 4
- 229960001570 ademetionine Drugs 0.000 claims description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 4
- 235000019158 vitamin B6 Nutrition 0.000 claims description 4
- 229940011671 vitamin b6 Drugs 0.000 claims description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- 206010016880 Folate deficiency Diseases 0.000 claims description 2
- 230000000975 bioactive effect Effects 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004994 reproductive system Anatomy 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 3
- 208000010188 Folic Acid Deficiency Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 150000002224 folic acids Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 claims 1
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 abstract description 40
- 235000000639 cyanocobalamin Nutrition 0.000 abstract description 20
- 239000011666 cyanocobalamin Substances 0.000 abstract description 20
- 229960002104 cyanocobalamin Drugs 0.000 abstract description 20
- 229940014144 folate Drugs 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000002950 deficient Effects 0.000 abstract description 2
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 19
- 238000007069 methylation reaction Methods 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 229940029329 intrinsic factor Drugs 0.000 description 9
- 230000011987 methylation Effects 0.000 description 8
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 208000031845 Pernicious anaemia Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 3
- 235000007672 methylcobalamin Nutrition 0.000 description 3
- 239000011585 methylcobalamin Substances 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 231100000683 possible toxicity Toxicity 0.000 description 3
- 235000019157 thiamine Nutrition 0.000 description 3
- 239000011721 thiamine Substances 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- ZIHHMGTYZOSFRC-UWWAPWIJSA-M cobamamide Chemical compound C1(/[C@](C)(CCC(=O)NC[C@H](C)OP(O)(=O)OC2[C@H]([C@H](O[C@@H]2CO)N2C3=CC(C)=C(C)C=C3N=C2)O)[C@@H](CC(N)=O)[C@]2(N1[Co+]C[C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C3=NC=NC(N)=C3N=C1)O)[H])=C(C)\C([C@H](C/1(C)C)CCC(N)=O)=N\C\1=C/C([C@H]([C@@]\1(CC(N)=O)C)CCC(N)=O)=N/C/1=C(C)\C1=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]1CCC(N)=O ZIHHMGTYZOSFRC-UWWAPWIJSA-M 0.000 description 2
- 235000006279 cobamamide Nutrition 0.000 description 2
- 239000011789 cobamamide Substances 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 description 2
- 235000007635 levomefolic acid Nutrition 0.000 description 2
- 239000011578 levomefolic acid Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- TZBGSHAFWLGWBO-ABLWVSNPSA-N (2s)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pteridin-6-yl)methylamino]benzoyl]amino]-5-methoxy-5-oxopentanoic acid Chemical compound C1=CC(C(=O)N[C@@H](CCC(=O)OC)C(O)=O)=CC=C1NCC1NC(C(=O)NC(N)=N2)=C2NC1 TZBGSHAFWLGWBO-ABLWVSNPSA-N 0.000 description 1
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- MZFOKIKEPGUZEN-AGCMQPJKSA-N (R)-methylmalonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)[C@@H](C(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MZFOKIKEPGUZEN-AGCMQPJKSA-N 0.000 description 1
- 102000011848 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Human genes 0.000 description 1
- 108010075604 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 description 1
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical group O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 241000341910 Vesta Species 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 231100000313 clinical toxicology Toxicity 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029039 cyanide poisoning Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 125000003929 folic acid group Chemical group 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037345 metabolism of vitamins Effects 0.000 description 1
- ZIYVHBGGAOATLY-UHFFFAOYSA-N methylmalonic acid Chemical compound OC(=O)C(C)C(O)=O ZIYVHBGGAOATLY-UHFFFAOYSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000005460 tetrahydrofolate Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to the field of treating vitamin deficiency conditions and to preparations for use in such treatment.
- Vitamin B 12 is a cobalt-containing vitamin which is involved in a number of biochemical reactions. The two most important are the conversion of homocysteine to methionine and the conversion of methylmalonyl-coenzyme A to succinyl-coenzyme A. Homocysteine is potentially harmful to many body tissues, including the vascular system and the nervous system, if it is present in excess. Methionine is required for the formation of S-adenosyl-methionine which is used as amethyl donor in many different essential reactions including the regulation of DNA and RNA function and the synthesis of phospholipids, neurotransmitters and complex carbohydrates.
- succinyl-coenzyme A is required for the normal metabolism of fats and carbohydrates. It is thus apparent that an inadequate supply of vitamin B 12 will lead to many different abnormalities in the body. The best known are the haematological abnormality of megaloblastic anaemia, and neurological damage which can lead to fatigue and to a range of neurological and psychiatric symptoms which are caused by loss of neuronal function proceeding to neurodegeneration.
- Vitamin B 12 has a particularly close interaction with folic acid.
- the conversion of homocysteine to methionine is achieved by the enzyme methionine synthetase where methyl-cobalamin plays an essential role.
- a required co-factor for this enzyme is folic acid in the form of 5-methyltetrahydrofolate: in the course of the reaction a methyl group is transferred from 5-methyltetrahydrofolate to homocysteine, so producing tetrahydrofolate and methionine.
- deficiencies of folic acid and of vitamin B 12 interact. This interaction is important both in the lowering of homocysteine and in the generation of S-adenosyl-methionine for methylation reactions.
- Methylation is increasingly being recognised as a reaction of central importance in many different reactions in all the tissues of the body, but particularly the brain, the liver and rapidly dividing tissues like the bone marrow, the gastrointestinal tract, the skin and the reproductive system.
- the methyl donor which plays the key role in over thirty reactions is S-adenosyl-methiocine (SAM) (T Bottiglieri et al, Drugs 1994, 48; 137-152. P K Chiang et al, FASEB J 1996; 10; 471-480. T Bottiglieri, Exp Opin Invest Drugs 1997; 6; 417-426. C S Lieber, J Hepatology 1999; 30; 1155-9).
- Methylation of the nucleic acids, DNA and RNA plays a central role in the regulation of gene function and expression. Methylation regulates the functions of many enzymes, including enzymes involved in the synthesis of the neurotransmitters noradrenaline, dopamine and serotonin. Methylation modulates the behaviour of many receptors, including those for noradrenaline, adrenaline, acetyl choline, gamma-amino-butyric acid and many other substances. Methylation is important in the synthesis of key membrane phospholipids and in the regulation of the properties of all the external and internal phospholipid-containing membranes of cells.
- Methylation is required for the normal synthesis of the polyamines, spermine and spermidine, which are important signalling molecules in many cells. Methylation is important in the synthesis of complex carbohydrates which modify many cell-cell interactions. Since vitamin B 12 and folic acid are absolutely required for the normal synthesis of SAM, it is clear that it is of central importance that they should always be available in all tissues in adequate amounts. Recently, SAM and stable derivatives thereof have themselves been developed as drugs, particularly for nervous system and liver diseases (Bottiglieri, 1997, Lieber, 1999).
- homocysteine can also be converted to cystathionine and then to cysteine in two successive reactions, both of which require vitamin B 6 as a co-factor. Excessive accumulation of homocysteine can thus be partially dealt with by its metabolism along this pathway. However, this cannot occur if there is inadequate availability of vitamin B 6 . Vitamin B 6 may, therefore, be of value in removing homocysteine, but not in generating SAM since it takes homocysteine out of the cycle.
- vitamin B 12 There are four main forms of vitamin B 12 , cyanocobalamin, hydroxocobalamin, methylcobalamin and adenosylcobalamin. Methylcobalamin and adenosylcobalamin are unstable and very easily damaged by light. They are therefore unsuitable for use in dietary supplements or pharmaceuticals and are not necessary since they can be formed from cyanocobalamin or hydroxocobalamin within the body.
- the main form of vitamin B 12 found in food is hydroxocobalamin (J Farquharson and J F Adams, British Journal of Nutrition 1976; 36:127-136).
- the main form used therapeutically and in nutritional supplements is cyanocobalamin, chosen because it is the most stable form and therefore easiest to synthesise and formulate. All oral nutritional and pharmaceutical preparations of vitamin B 12 which are commercially available use cyanocobalamin .
- vitamin B 12 is absorbed from the gastro-intestinal tract with the acid of a specific binding protein, known as intrinsic factor (IF) which is produced by the stomach.
- IF intrinsic factor
- the normal daily requirement for vitamin B 12 is in the region of 0.1 to 2.0 microg/day according to various expert committees.
- the daily loss of vitamin B 12 can be then considerably increased, at the same time as the food-bound vitamin B 12 cannot be absorbed.
- a lack of IF thus produces a deficit of vitamin B 12 within the body even though there are apparently adequate amounts in the food.
- the deficiency known as pernicious anaemia, is treated by injections of vitamin B 12 as cyanocobalamin or hydroxocobalamin as it is generally believed that oral administration of vitamin B 12 will be ineffective.
- vitamin B 12 deficiency states are much commoner in the general population, especially the older population, in smokers, and in those at risk of cardiovascular disease than had previously been thought.
- One marker of this is an elevated level of homocysteine in plasma.
- 44 apparently healthy men had elevated levels of homocysteine coupled with highly significantly subnormal blood levels of vitamin B 12 (J B Ubbink et al, American Journal of Clinical Nutrition 1993; 57:47-53).
- a high proportion of older outpatients attending a clinic had deficiencies of vitamin B 12 (L C Pennypacker et al, Journal of the American Geriatric Society 1992; 40:1197-1204).
- cyanocobalamin may be less than optimum and may even be toxic in individuals with vitamin B 12 deficiency.
- One reason is that there appear to be adverse interactions between vitamin B 12 deficiency and the presence of cyanide.
- Cyanide is relatively common at low levels in the environment, being present in smoke, particularly tobacco smoke, and in certain foods. It my also be generated in small amounts in the course of normal metabolism since the body contains effective mechanisms for cyanide detoxification.
- the formulation should provide a minimum dose of 0.5 mg hydroxocobalamin per day, should sometimes include more than 5 mg/day and should provide a maximum dose of 50 mg per day, preferably within the range of 1 mg per day to 10 mg/day.
- the hydroxocobalamin should be formulated with folic acid or a related bioactive derivative also providing a minimum of 0.5 mg folate per day and a maximum of 50 mg/day.
- a patent EP-A-35 0558960 in the name of Wörwag discloses primarily the use of thiamin, in association with other nutrients, in medicaments for patients who are abusing alcohol.
- This specification describes folic acid and vitamin B 12 as additional ingredients to thiamine in such a medicament.
- Any form of vitamin B 12 is described as being acceptable in the formulation, with no discussion of the possible toxicity of cyanocobalamin or of the advantages of hydroxocobalamin.
- Thiamine is always an essential component and the specification does not disclose the value of formulation of hydroxocobalamin and folic acid.
- E-A-0595005 Vesta discloses the combination of three nutrients, folic acid, vitamin B 12 and vitamin B 6 , specifically for the treatment of elevated homocysteine levels. Vitamin B6 is absolutely required in this formulation.
- the source of vitamin B12 is stated as being cyanocobalamin or hydroxocobalamin. There is no suggestion that hydroxocobalamin is the preferred form, or that cyanocobalamin may potentially be toxic. All of the examples of oral products specifically refer to cyanocobalamin and not to hydroxocobalamin.
- a paper by M den Heijer et al discusses the administration of a formulation for lowering homocysteine levels comprising 0.4 mg of hydroxocobalamin, either alone or with 0.5 mg/day or 5 mg/day of folic acid.
- the authors found that hydroxocobalamin contributed little to the lowering of homocysteine levels with the main effect being due to folic acid.
- the dose of hydroxocobalamin in this citation is lower than provided for in the present specification and is probably too low to be consistently beneficial in individuals who have any problems in the absorption or metabolism of vitamin B 12 .
- SAM S-adenosyl-homocysteine
- administration of SAM has the potential to increase the formation of homocysteine substantially, particularly in patients with deficits of folic acid or vitamin B 12 who may not be able to metabolise the homocysteine normally. It will therefore be particularly appropriate to include hydroxocobalamin and folic acid in formulations of SAM or derivatives of SAM for any therapeutic purpose for which the SAM is being administered.
- Other ingredients may optionally be added to the basic hydroxocobalamin/folate formulation. These may include any other essential nutrients and any drugs. Such formulations will be particularly appropriate when treatment is given to a population which seems to be at particular risk of, or particularly affected by single or combined deficiencies of vitamin B 12 or folate.
- Such patients include all elderly patients being treated for any disease, all patients of any age being treated for psychiatric or neurological diseases including patients with depression, bipolar disorder, schizophrenia, multiple sclerosis, dementias including Alzheimer's disease, panic attacks, anxiety, social phobia, and Parkison's disease, all patients with fatigue of any origin, and all patients with or at risk of cardiovascular diseases, liver diseases, gastrointestinal, reproductive or skin diseases, or any other diseases.
- a sugar-flavoured powder containing between 0.5 and 50 mg of hydroxocobalamin and between 0.5 mg and 50 mg of folic acid in 5 g.
- Multinutrient formulations for oral use containing a range of essential nutrients, in which are included folic acid and hydroxocobalamin as specified in examples 1-6.
- a drug for oral use the treatment of any disease whose daily formulation includes hydroxocobalamin and folic acid as in formulation 1.
- a drug for oral use in cardiovascular disease formulated as in 13.
- SAM S-adenosyl-methionine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
- This invention relates to the field of treating vitamin deficiency conditions and to preparations for use in such treatment.
- Vitamin B12 is a cobalt-containing vitamin which is involved in a number of biochemical reactions. The two most important are the conversion of homocysteine to methionine and the conversion of methylmalonyl-coenzyme A to succinyl-coenzyme A. Homocysteine is potentially harmful to many body tissues, including the vascular system and the nervous system, if it is present in excess. Methionine is required for the formation of S-adenosyl-methionine which is used as amethyl donor in many different essential reactions including the regulation of DNA and RNA function and the synthesis of phospholipids, neurotransmitters and complex carbohydrates. The formation of succinyl-coenzyme A is required for the normal metabolism of fats and carbohydrates. It is thus apparent that an inadequate supply of vitamin B12 will lead to many different abnormalities in the body. The best known are the haematological abnormality of megaloblastic anaemia, and neurological damage which can lead to fatigue and to a range of neurological and psychiatric symptoms which are caused by loss of neuronal function proceeding to neurodegeneration.
- Vitamin B12 has a particularly close interaction with folic acid. The conversion of homocysteine to methionine is achieved by the enzyme methionine synthetase where methyl-cobalamin plays an essential role. A required co-factor for this enzyme is folic acid in the form of 5-methyltetrahydrofolate: in the course of the reaction a methyl group is transferred from 5-methyltetrahydrofolate to homocysteine, so producing tetrahydrofolate and methionine. As a result of this reaction deficiencies of folic acid and of vitamin B12 interact. This interaction is important both in the lowering of homocysteine and in the generation of S-adenosyl-methionine for methylation reactions.
- Methylation is increasingly being recognised as a reaction of central importance in many different reactions in all the tissues of the body, but particularly the brain, the liver and rapidly dividing tissues like the bone marrow, the gastrointestinal tract, the skin and the reproductive system. The methyl donor which plays the key role in over thirty reactions is S-adenosyl-methiocine (SAM) (T Bottiglieri et al, Drugs 1994, 48; 137-152. P K Chiang et al, FASEB J 1996; 10; 471-480. T Bottiglieri, Exp Opin Invest Drugs 1997; 6; 417-426. C S Lieber, J Hepatology 1999; 30; 1155-9). Methylation of the nucleic acids, DNA and RNA, plays a central role in the regulation of gene function and expression. Methylation regulates the functions of many enzymes, including enzymes involved in the synthesis of the neurotransmitters noradrenaline, dopamine and serotonin. Methylation modulates the behaviour of many receptors, including those for noradrenaline, adrenaline, acetyl choline, gamma-amino-butyric acid and many other substances. Methylation is important in the synthesis of key membrane phospholipids and in the regulation of the properties of all the external and internal phospholipid-containing membranes of cells. Methylation is required for the normal synthesis of the polyamines, spermine and spermidine, which are important signalling molecules in many cells. Methylation is important in the synthesis of complex carbohydrates which modify many cell-cell interactions. Since vitamin B12 and folic acid are absolutely required for the normal synthesis of SAM, it is clear that it is of central importance that they should always be available in all tissues in adequate amounts. Recently, SAM and stable derivatives thereof have themselves been developed as drugs, particularly for nervous system and liver diseases (Bottiglieri, 1997, Lieber, 1999).
- As well as being converted to methionine, homocysteine can also be converted to cystathionine and then to cysteine in two successive reactions, both of which require vitamin B6 as a co-factor. Excessive accumulation of homocysteine can thus be partially dealt with by its metabolism along this pathway. However, this cannot occur if there is inadequate availability of vitamin B6. Vitamin B6 may, therefore, be of value in removing homocysteine, but not in generating SAM since it takes homocysteine out of the cycle.
- There are four main forms of vitamin B12, cyanocobalamin, hydroxocobalamin, methylcobalamin and adenosylcobalamin. Methylcobalamin and adenosylcobalamin are unstable and very easily damaged by light. They are therefore unsuitable for use in dietary supplements or pharmaceuticals and are not necessary since they can be formed from cyanocobalamin or hydroxocobalamin within the body. The main form of vitamin B12 found in food is hydroxocobalamin (J Farquharson and J F Adams, British Journal of Nutrition 1976; 36:127-136). The main form used therapeutically and in nutritional supplements is cyanocobalamin, chosen because it is the most stable form and therefore easiest to synthesise and formulate. All oral nutritional and pharmaceutical preparations of vitamin B12 which are commercially available use cyanocobalamin .
- In normal individuals vitamin B12 is absorbed from the gastro-intestinal tract with the acid of a specific binding protein, known as intrinsic factor (IF) which is produced by the stomach. The normal daily requirement for vitamin B12 is in the region of 0.1 to 2.0 microg/day according to various expert committees. There is normally an extensive enterohepatic recovery of vitamin B12. This recovery is impaired if IF is lacking, if the distal ileum is damaged, e.g. by radiation or disease, or has been removed by surgery. The daily loss of vitamin B12 can be then considerably increased, at the same time as the food-bound vitamin B12 cannot be absorbed. A lack of IF thus produces a deficit of vitamin B12 within the body even though there are apparently adequate amounts in the food. The deficiency, known as pernicious anaemia, is treated by injections of vitamin B12 as cyanocobalamin or hydroxocobalamin as it is generally believed that oral administration of vitamin B12 will be ineffective.
- However, it is not well known that it is possible to treat vitamin B12 deficiency by oral administration of mg-doses even in the absence of IF, or when absorption is disturbed by other causes. This is because there is also a passive diffusion of the vitamin through the intestinal wall into the body without any need for IF. The passive absorption is dose-dependent and amounts to about 1-2% of doses of 1 mg or more. Two studies using cyanocobalamin have shown that oral doses of 1-2 mg/day are fully adequate to provide vitamin B12 even in patients with pernicious anaemia (H Berlin et al, Acta Medica Scandinavica 1968; 184:247-258: AM Kuzminski et al, Blood 1998; 92:1191-8). Long-term oral treatment with 1 mg cyanocarbalamin per day has been calculated to restore the body stores of vitamin B12 to the same extent as 1 mg hydroxocobalamin given by injection each third month (Berlin R et al, Acta Medaica Scand. 1978; 204:81-4). However it is not well known by doctors that a vitamin B12 deficiency can be treated orally: in a survey of 245 internal medicine specialists in Minnesota none had used oral vitamin B12 to treated pernicious anaemia and only 1% had used oral vitamin B12 to treat a dietary deficiency: injection of cyanocobalamin was the treatment used by these doctors (F A Lederle, JAMA 1991; 265:94-95).
- Recent studies have demonstrated that vitamin B12 deficiency states are much commoner in the general population, especially the older population, in smokers, and in those at risk of cardiovascular disease than had previously been thought. One marker of this is an elevated level of homocysteine in plasma. For example, 44 apparently healthy men had elevated levels of homocysteine coupled with highly significantly subnormal blood levels of vitamin B12 (J B Ubbink et al, American Journal of Clinical Nutrition 1993; 57:47-53). A high proportion of older outpatients attending a clinic had deficiencies of vitamin B12 (L C Pennypacker et al, Journal of the American Geriatric Society 1992; 40:1197-1204). In a Massachusetts population 40.5% of older individuals and 17.9% of younger people were found to have low or low normal serum vitamin B12 (J Lindenbaum et al, American Journal of Clinical Nutrition 1994; 60:2-11). In Europe 63% of healthy elderly people were found to have an elevated level of homocysteine or methylmalonic acid, or other markers of vitamin B12 deficiency (E Joosten et al, American Journal of Clinical Nutrition 1993; 58: 468-76). In healthy older Dutch people, 23.8% were found to be vitamin B12 deficient (DZB van Asselt et al, American Journal of Clinical Nutrition 1998; 68:328-334). In many of the individuals reported in these studies there were also deficiencies of folate and sometimes of vitamin B5 which exaggerated the problems associated with vitamin B12 deficiency.
- Most of the people with these deficiencies apparently have adequate vitamin B12 levels in the diet. Their problems must therefore relate to inadequate levels of IF or to some other metabolic problem. If there are deficits of IF, standard medical treatment is to give injections of vitamin as hydroxocobalamin or cyanocobalamin and not oral treatment. However, to give regular injections to the very large numbers of apparently healthy people affected by vitamin B12 deficiency is clearly not a practical proposition. Oral vitamin B12 is usually given only when there is a dietary deficiency. Then the form of the vitamin which is given is always cyanocobalamin: no oral preparations of hydroxocobalamin are available.
- Surprisingly, we have noted that cyanocobalamin may be less than optimum and may even be toxic in individuals with vitamin B12 deficiency. One reason is that there appear to be adverse interactions between vitamin B12 deficiency and the presence of cyanide. Cyanide is relatively common at low levels in the environment, being present in smoke, particularly tobacco smoke, and in certain foods. It my also be generated in small amounts in the course of normal metabolism since the body contains effective mechanisms for cyanide detoxification. There is evidence that the consequences of vitamin B12 deficiency for the nervous system are much more serious in the presence of situations where cyanide may be generated or not detoxified (A G Freeman, Journal of the Royal Society of Medicine 1988; 81:103-106: A G Freeman, Journal of the Royal Society of Medicine 1992; 85:686-7). Whereas cyanocobalamin will not alleviate any cyanide excess and may even make the situation worse because of its cyanide content, hydroxocobalamin not only corrects a vitamin B12 deficiency but actually acts as an antidote to cyanide poisoning by binding cyanide (J C Forsyth et al, Clinical Toxicology 1993; 31:277-294). On the basis of these observations, therefore, Freeman has argued that cyanocobalamin should actually be withdrawn and replaced by hydroxocobalamin. However, Freeman has also argued that only hydroxocobalamin given by injection should be used, stating “I strongly oppose any treatment for pernicious anaemia other than parenteral hydroxocobalamin” (A G Freeman 1999; Lancet 353 4I0-411).
- In view of the widespread occurrence of vitamin B12 deficiency states in the general population, in view of the fact that most of these deficiency states are not due to lack of vitamin B12 in food, and in view of the potential toxicity or lack of efficacy of high doses of cyanocobalamin, we propose the formulation of high doses of hydroxocobalamin for oral administration. Furthermore in view of the very common co-occurrence of folate deficiency in these same populations and in view of the fact that folate and vitamin B12 are so closely linked metabolically we propose that the hydroxocobalamin should always be formulated with folic acid or a related compound with folate bioactivity such as methyltetrahydrofolate. Such formulations will be particularly valuable in generating SAM for methylation reactions.
- In order to ensure adequate absorption of vitamin B12, even in the absence of intrinsic factor, we propose that the formulation should provide a minimum dose of 0.5 mg hydroxocobalamin per day, should sometimes include more than 5 mg/day and should provide a maximum dose of 50 mg per day, preferably within the range of 1 mg per day to 10 mg/day. The hydroxocobalamin should be formulated with folic acid or a related bioactive derivative also providing a minimum of 0.5 mg folate per day and a maximum of 50 mg/day.
- There is an extensive literature relating to the uses of folic acid and of vitamin B12, particularly in relation to the lowering of homocysteine levels. There is less literature relating to their uses in situations where enhancement of methylation is important. Almost all of the literature deals with the use of folic acid combined with cyanocobalamin as the source of the vitamin B12. Occasional authors mention hydroxocobalamin in passing as a possible alternative source, but none emphasises or even discusses the advantages of using hydroxocobalamin in view of the potential toxicity of cyanocobalamin.
- Three citations are of particular importance in the context of the combined use of high or relatively high doses of vitamin B12 and folic acid. A patent EP-A-35 0558960 in the name of Wörwag discloses primarily the use of thiamin, in association with other nutrients, in medicaments for patients who are abusing alcohol. This specification describes folic acid and vitamin B12 as additional ingredients to thiamine in such a medicament. Any form of vitamin B12 is described as being acceptable in the formulation, with no discussion of the possible toxicity of cyanocobalamin or of the advantages of hydroxocobalamin. Thiamine is always an essential component and the specification does not disclose the value of formulation of hydroxocobalamin and folic acid.
- E-A-0595005 Vesta discloses the combination of three nutrients, folic acid, vitamin B12 and vitamin B6, specifically for the treatment of elevated homocysteine levels. Vitamin B6 is absolutely required in this formulation. The source of vitamin B12 is stated as being cyanocobalamin or hydroxocobalamin. There is no suggestion that hydroxocobalamin is the preferred form, or that cyanocobalamin may potentially be toxic. All of the examples of oral products specifically refer to cyanocobalamin and not to hydroxocobalamin.
- A paper by M den Heijer et al (Arteriosoler Thromb Vasc Biol 1998; 18; 356-61) discusses the administration of a formulation for lowering homocysteine levels comprising 0.4 mg of hydroxocobalamin, either alone or with 0.5 mg/day or 5 mg/day of folic acid. The authors found that hydroxocobalamin contributed little to the lowering of homocysteine levels with the main effect being due to folic acid. The dose of hydroxocobalamin in this citation is lower than provided for in the present specification and is probably too low to be consistently beneficial in individuals who have any problems in the absorption or metabolism of vitamin B12.
- Thus, none of the prior art describes the specific importance of higher oral doses of hydroxocobalamin of 0.5 mg/day or above when combined with folic acid. None of the prior art discusses the specific uses of hydroxocobalamin and folic acid to promote the synthesis of SAM for methylation reactions.
- As discussed above, there is increasing interest in using SAM, or derivatives of SAM, as therapeutic agents themselves for the promotion of methylation reactions. Once SAM has donated its methyl group, the molecule left is S-adenosyl-homocysteine; which is rapidly converted to homocysteine. Thus, administration of SAM has the potential to increase the formation of homocysteine substantially, particularly in patients with deficits of folic acid or vitamin B12 who may not be able to metabolise the homocysteine normally. It will therefore be particularly appropriate to include hydroxocobalamin and folic acid in formulations of SAM or derivatives of SAM for any therapeutic purpose for which the SAM is being administered.
- Other ingredients may optionally be added to the basic hydroxocobalamin/folate formulation. These may include any other essential nutrients and any drugs. Such formulations will be particularly appropriate when treatment is given to a population which seems to be at particular risk of, or particularly affected by single or combined deficiencies of vitamin B12 or folate. Such patients include all elderly patients being treated for any disease, all patients of any age being treated for psychiatric or neurological diseases including patients with depression, bipolar disorder, schizophrenia, multiple sclerosis, dementias including Alzheimer's disease, panic attacks, anxiety, social phobia, and Parkison's disease, all patients with fatigue of any origin, and all patients with or at risk of cardiovascular diseases, liver diseases, gastrointestinal, reproductive or skin diseases, or any other diseases. These populations for various reasons are often at risk of nutritional deficiencies and deficiencies of vitamin B12 or folic acid may often limit the desired therapeutic responses to drug treatment of any of the above illnesses. It is therefore within the scope of the invention to add hydroxocobalamin and folic acid to any oral formulation of any drug for the treatment of the above diseases.
- 1. A tablet or hard or soft gelatin capsule containing between 0.5 and 50 mg of hydroxocobalamin together with between 0.5 mg and 50 mg of folic acid.
- 2. A flavoured syrup containing in 5 ml between 0.5 and 50 mg of hydroxocobalamin together with between 0.5 mg and 50 mg of folic acid.
- 3. A sugar-flavoured powder containing between 0.5 and 50 mg of hydroxocobalamin and between 0.5 mg and 50 mg of folic acid in 5 g.
- 4-6. As 1-3 but containing in addition 2-10 mg of vitamin B6.
- 7-12. Multinutrient formulations for oral use containing a range of essential nutrients, in which are included folic acid and hydroxocobalamin as specified in examples 1-6.
- 13. A drug for oral use, the treatment of any disease whose daily formulation includes hydroxocobalamin and folic acid as in formulation 1.
- 14. A drug for oral use in cardiovascular disease formulated as in 13.
- 15. A drug for oral use in psychiatric or neurological disease formulated as in 13.
- 16. A drug for oral use in the treatment of any disease in people over the age of 40 formulated as in 13.
- 17. S-adenosyl-methionine (SAM), or derivatives of SAM, formulated for oral administration as in 13.
Claims (15)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9906740.7A GB9906740D0 (en) | 1999-03-23 | 1999-03-23 | Oral combinations of hydroxocobalamin and folic acid |
GBGB9906740.7 | 1999-03-23 | ||
GB9906740 | 1999-03-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
US20020010148A1 true US20020010148A1 (en) | 2002-01-24 |
US6369041B2 US6369041B2 (en) | 2002-04-09 |
Family
ID=10850240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/534,417 Expired - Lifetime US6369041B2 (en) | 1999-03-23 | 2000-03-23 | Oral combinations of hydroxocobalamin and folic acid |
Country Status (6)
Country | Link |
---|---|
US (1) | US6369041B2 (en) |
EP (1) | EP1210089A2 (en) |
AU (1) | AU3441500A (en) |
CA (1) | CA2366899A1 (en) |
GB (1) | GB9906740D0 (en) |
WO (1) | WO2000056295A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050032740A1 (en) * | 2003-08-06 | 2005-02-10 | Balaji Venkataraman | Vitamin compositions for the treatment and prevention of vascular disease and dementia |
US20050032741A1 (en) * | 2003-08-06 | 2005-02-10 | Balaji Venkataraman | Vitamin Compositions |
US20050084459A1 (en) * | 2001-06-26 | 2005-04-21 | Reznick Abraham Z. | Filters for preventing or reducing tobacco smoke-associated injury in the aerodigestive tract of a subject |
WO2005072749A1 (en) * | 2004-01-29 | 2005-08-11 | Halevie-Goldman, Brian, D. | Compositions and methods for homocsyteine regulation |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6265391B1 (en) | 1995-10-17 | 2001-07-24 | Upsher-Smith Laboratories, Inc. | Method for preventing peripheral nerve damage |
JP2004526793A (en) * | 2001-04-25 | 2004-09-02 | コバルツ リミテッド | Methods for treating or preventing functional vitamin B12 deficiency in an individual, and medical compositions for use in the methods |
US20080045448A1 (en) * | 2006-08-18 | 2008-02-21 | Alan Robert Vinitsky | Reversing autonomic nervous system dysfunction by potentiating methylation |
FR3004649A1 (en) * | 2013-04-18 | 2014-10-24 | Bruno Eto | COMPOSITION COMPRISING HYDROXOCOBALAMINE FOR ITS USE IN THE ORAL TREATMENT OF VITAMIN B12 DEFICIT AND ASSOCIATED DISEASES |
AT14825U1 (en) * | 2014-11-10 | 2016-07-15 | Eduard Rappold | Combination preparation containing ademetionin and vitamin B12 for the treatment and prevention of Alzheimer's disease type I (LOAD) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB821398A (en) | 1957-11-26 | 1959-10-07 | Smith Kline French Lab | Improvements in or relating to liquid vitamin preparation |
AP387A (en) * | 1991-09-13 | 1995-07-31 | Siegbert Heinrich Bissbort | Therapeutical uses of L-methionine and compositions thereof. |
DE4206422C2 (en) * | 1992-02-29 | 1996-07-11 | Woerwag Pharma Gmbh | Medicines for the prophylaxis and treatment of neurological and psychiatric damage caused by alcohol abuse |
CA2105177A1 (en) | 1992-09-14 | 1994-03-15 | Willem Jacob Serfontein | Pharmaceutical preparations for lowering homocysteine levels |
US5795873A (en) * | 1992-12-29 | 1998-08-18 | Metabolite Laboratories, Inc. | Method for treatment and prevention of deficiencies of vitamins B12, folic acid and B6 |
DE4326698C2 (en) * | 1993-08-09 | 1997-05-28 | Puetter Medice Chem Pharm | Use of a combination of folic acid, vitamin B¶6¶ and vitamin B¶1¶¶¶¶ for the prevention and treatment of arteriosclerosis |
US6121249A (en) * | 1998-07-01 | 2000-09-19 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins |
US6129918A (en) * | 1998-08-13 | 2000-10-10 | Wakunaga Of America Co., Ltd. | Method and pharmaceutical composition for reducing serum homocysteine concentration |
DK0951842T3 (en) | 1999-01-20 | 2003-01-06 | Nutricia Nv | Nutritional product for an infant |
-
1999
- 1999-03-23 GB GBGB9906740.7A patent/GB9906740D0/en not_active Ceased
-
2000
- 2000-03-23 US US09/534,417 patent/US6369041B2/en not_active Expired - Lifetime
- 2000-03-23 AU AU34415/00A patent/AU3441500A/en not_active Abandoned
- 2000-03-23 CA CA002366899A patent/CA2366899A1/en not_active Abandoned
- 2000-03-23 EP EP00912767A patent/EP1210089A2/en not_active Withdrawn
- 2000-03-23 WO PCT/GB2000/001093 patent/WO2000056295A2/en not_active Application Discontinuation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050084459A1 (en) * | 2001-06-26 | 2005-04-21 | Reznick Abraham Z. | Filters for preventing or reducing tobacco smoke-associated injury in the aerodigestive tract of a subject |
US20050032740A1 (en) * | 2003-08-06 | 2005-02-10 | Balaji Venkataraman | Vitamin compositions for the treatment and prevention of vascular disease and dementia |
US20050032741A1 (en) * | 2003-08-06 | 2005-02-10 | Balaji Venkataraman | Vitamin Compositions |
WO2005072749A1 (en) * | 2004-01-29 | 2005-08-11 | Halevie-Goldman, Brian, D. | Compositions and methods for homocsyteine regulation |
Also Published As
Publication number | Publication date |
---|---|
GB9906740D0 (en) | 1999-05-19 |
WO2000056295A3 (en) | 2002-03-28 |
AU3441500A (en) | 2000-10-09 |
WO2000056295A2 (en) | 2000-09-28 |
CA2366899A1 (en) | 2000-09-28 |
EP1210089A2 (en) | 2002-06-05 |
US6369041B2 (en) | 2002-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050147665A1 (en) | Pharmaceutical and nutritional compositions | |
JPH09504036A (en) | Dietary supplements that optimize cell health | |
US20020002146A1 (en) | Compositions and methods for the production of S-adenosylmethionine within the body | |
Spillmann et al. | S-adenosylmethionine (Ademetionine) in psychiatric disorders: historical perspective and current status | |
US20170274002A1 (en) | Multiple folate formulation and use thereof | |
US20220378731A1 (en) | Composition For Treating Tauopathy In The Brain, Brain Stem and Spinal Column | |
JP2002528507A (en) | Composition for the treatment and prevention of neurological and pathopsychological diseases | |
US6369041B2 (en) | Oral combinations of hydroxocobalamin and folic acid | |
Bottiglieri et al. | S-adenosylmethionine | |
EP2723448B1 (en) | Compositions for the treatment of chronic fatigue | |
JP2005525329A (en) | A compound consisting of psychotropic drugs and selenium | |
JP2003113086A (en) | Method for curing attention deficit hyperkinetic syndrome with phosphatidylserine | |
Hardy et al. | Nutraceuticals: a pharmaceutical viewpoint: I | |
US20090215714A1 (en) | Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder | |
RU2709500C1 (en) | Pharmaceutical composition for parenteral drip introduction | |
JP4773015B2 (en) | Treatment of migraine by administration of alpha lipoic acid or its derivatives | |
US20030194453A1 (en) | Dietary supplement | |
CA2507887A1 (en) | Nucleotide based medicament and method of use for treatment of conditions in humans | |
JPH02235809A (en) | Use of lecithin in recovery of smelling and tasting sense | |
JPH04342528A (en) | Agent for promotion of alcohol metabolism and acetaldehyde metabolism | |
Esperanca | The wonders of vitamin B12: Keep Sane and Young | |
US20150080402A1 (en) | Compositions And Methods For Treatment Of Psychiatric Disorders | |
RU2720134C1 (en) | Pharmaceutical composition for parenteral drop introduction | |
CN102389564A (en) | Compositions for use in treating myelodysplastic syndrome | |
RU2721606C1 (en) | Pharmaceutical composition for parenteral drop introduction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KILGOWAN LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HORROBIN, DAVID FREDERICK;GOUAILLE, CHRISTINA;REEL/FRAME:010963/0564;SIGNING DATES FROM 20000703 TO 20000706 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
REMI | Maintenance fee reminder mailed | ||
AS | Assignment |
Owner name: GOUAILLE, CHRISTINA, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KILGOWAN LIMITED;REEL/FRAME:032351/0338 Effective date: 20091001 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
SULP | Surcharge for late payment |
Year of fee payment: 11 |